ARGX-117

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Kidney TransplantNeuropathy

121 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

1

Ultomiris

AstraZeneca

Phase 3

12

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

33

Felzartamab

Biogen

Phase 3

14

Biological/vaccine

Vertex Pharmaceuticals

Phase 3

15

Envarsus XR

UUniversity of Wisconsin, Madison

Phase 3

26

Zemplar

AbbVie

Preclinical

27

Radicava

Shionogi

Preclinical

18

Cysteine Hydrochloride

Novartis

Preclinical

19

Sensipar

Amgen

Preclinical

110

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1Show 25 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Neuropathy2 trials

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy

Active, not recruiting·Argenx·Phase 2·NCT05405361·51 enrolled

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy

Completed·Argenx·Phase 2·NCT05225675·54 enrolled

Kidney Transplant1 trial

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

Active, not recruiting·Argenx·Phase 2·NCT05907096·103 enrolled

Unspecified1 trial

SAD and MAD Study With IV and SC Doses of ARGX-117

Completed·Argenx·Phase 1·NCT04532125·110 enrolled

Details

Drug Info

Related News